Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Open Access
- 1 August 2006
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 70 (3), 536-542
- https://doi.org/10.1038/sj.ki.5001580
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Beneficial impact of spironolactone in diabetic nephropathyKidney International, 2005
- Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patientsDiabetologia, 2005
- Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathyKidney International, 2004
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Remission of Nephrotic-Range Albuminuria in Type 1 Diabetic PatientsDiabetes Care, 2001
- Remission of nephrotic range proteinuria in type I diabetesKidney International, 1994
- Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatmentDiabetologia, 1994
- Prognosis in diabetic nephropathy.BMJ, 1989
- The Natural History of Diabetic Renal DiseaseA FOLLOW-UP STUDY OF A SERIES OF RENAL BIOPSIESQJM: An International Journal of Medicine, 1972